Dr Mark Babizhayev on Maintaining Healthy Eyes

Russian bio-physicist Dr Mark Babizhayev is one of the principal researchers behind the development of Can-C, a patented eye lubricant that also contains N-acetylcarnosine (NAC), an antioxidant that has been studied in humans with cataracts.

Dr Babizhayev’s work has led to numerous breakthroughs in eye care, and the Can-C eye drops he helped develop are one of Antiaging Nutrition’s best-selling products.

With this in mind, we’ve taken a further look at the man behind the product and collected together a number of interviews and resources to which the doctor has contributed over the years.

So let’s review Dr Babizhayev’s thoughts on eye care and take a look at the doctor’s advice on maintaining healthy eyes.

History of Research

Currently Executive Director at Innovative Vision Products, Inc. and Senior Research Investigator at the Moscow Helmholtz Research Institute of Eye Diseases, Dr Babizhayev has a rich and illustrious history in the medical world. His accomplishments include graduating from the Second Moscow Medical Institute’s Medico-Biological Faculty as a doctor-biophysicist in 1982, gaining a Ph.D. in Biophysics and Pathophysiology at the Moscow Helmholtz Research Institute of Eye Diseases in 1988 and receiving the prestigious Oka Memorial Award in Japan in 1992.

He has dedicated many years of his life to scientific research, and has accumulated over 86 published articles; he also has 15 patents to his name.

Dr Babizhayev’s latest research has seen him heavily involved in the development of a breakthrough for the treatment and prevention of senile cataracts. As a result, he was the first to present the remarkable results of using NAC against senile cataracts to a Western audience

But what led him to this breakthrough?

The Secrets of NAC

As Dr Babizhayev has stated, he first realised that NAC had potential as a potent ophthalmic drug in 1991 after completing the first pharmacokinetic studies with executives Dr Edoardo Bozzo Costa and Ovidio Caveri of Bruschettini S.r.l.

“[The studies] showed that NAC can act in vivo as a pro-drug of L-carnosine in ophthalmic application, as an antioxidant.”

These first experiments involved carefully testing the drops on animals, running tests with rabbits and canines affected by age-related cataracts.

Through the chronic use of these drops, the doctor noticed positive results within just one month:

“The cortical appearance of cataract reversal starts from the periphery and then the lens becomes more transparent. This is then accompanied by the improved visual behaviour of the animal […]. The striking results of reversing the cataract and the prevention of the lens opacities are clear.”

Testing Against Cataracts

Dr Babizhayev then proceeded to human clinical trials, utilising the latest technology to measure the effects of NAC.

Tools such as “interactive digital image analysis and 3D computer graphics” were used to measure the tiniest of changes in the subject’s eye lens opacity, and the results were outstanding.

After a six-month follow-up exam, “41.5% of the eyes treated with NAC presented a significant improvement in visual acuity of 7-100% and 88.9% of the eyes ranged a 27-100% improvement in glare sensitivity.”

The whole study lasted for 24 months and helped uncover the sustainable effects of NAC.

Can-C Eye Drops

Armed with a wealth of successful studies, Dr Babizhayev was able to work with Innovative Vision Products, Inc. to develop what has been labeled “one of the most exciting anti-aging products to emerge in recent years” by IAS Group’s Vice President, Phil Micans.

Can-C Eye Drops are a patented eye lubricant that contain the NAC ingredient used by Dr Babizhayev when testing against cataract.

You can discover more about NAC and Can-C Eye Drops, as well as the research led by Dr Babizhayev, in the video below.

For all the latest information on maintaining your health as you age, be sure to subscribe to our newsletter, and for more details about Can-C Eye Drops, contact a member of the Antiaging Nutrition staff today.